Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pledge Therapeutics
Canton, Massachusetts, United Statespledge-tx.com ↗
- Ownership
- Private
- Employees
- ~16
- Development stage
- Other
01
Overview
Pledge Therapeutics uses advanced structure-based drug discovery to develop first-in-class small molecule therapeutics against challenging disease targets. Their initial focus includes antivirals for BK and JC polyomavirus infections in transplant patients. The company has announced preclinical progress on its HHLA2 and IL18BP programs as well as the development of a first antiviral targeting BK virus. No clinical results have been published yet; all lead assets are preclinical.
- Therapeutic areas
- OtherOncologyInfectious Diseases
- Modalities
- small molecules
- Industry
- Biotech
Beyond the preview
Go deeper on Pledge Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pledge Therapeutics.